Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 7:14:26.
doi: 10.1186/1471-2377-14-26.

Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review

Richard J Bright  1 , Jenny Wilkinson, Brendon J Coventry
Affiliations

Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review

Richard J Bright et al. BMC Neurol. .

Abstract

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more than two months. Many individuals with chronic inflammatory demyelinating polyradiculoneuropathy fail to make a long-term recovery with current treatment regimes. The aim of this study was to prospectively review the literature to determine the effectiveness of therapies for chronic inflammatory demyelinating polyradiculoneuropathy.

Methods: Articles published from January 1990 to December 2012 were searched for studies to treat adults with chronic inflammatory demyelinating polyradiculoneuropathy. Peer-reviewed full-text articles published in English were included.

Results: Nine placebo-controlled double-blinded randomised trials were reviewed to treat subjects with chronic inflammatory demyelinating polyradiculoneuropathy exhibiting various degrees of effectiveness. The most effect treatments were; three randomised controlled trials using intravenous immunoglobulin, a study comparing pulsed dexamethasone and short term prednisolone and rituximab all showed promising results and were well tolerated.

Conclusion: IVIg and corticosteroids remain first line treatments for CIDP. Therapies using monoclonal antibodies, such as Rituximab and Natalizumab offer the most promise for treatment of Chronic inflammatory demyelinating polyradiculoneuropathy however they also need further research, as does the use of stem cell therapy for treating Chronic inflammatory demyelinating polyradiculoneuropathy. Large randomised controlled trials and better patient selection are required to address responsiveness of CIDP patients to conventional treatments to elucidate mechanisms of action and future directions for therapeutic improvement.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta-analysis of studies to improve recovery of CIDP versus control groups. Odds ratios are presented with 95 percent confidence intervals. Overall effect is shown using DerSimonian-Laird (DL) binary random- effect model.
Figure 2
Figure 2
Flow diagram showing selection of articles for review.
See this image and copyright information in PMC

References

    1. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2006;11(1):30–46. doi: 10.1111/j.1085-9489.2006.00061.x. - DOI - PubMed
    1. Dalakas MC. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. J Peripher Nerv Syst. 2012;17(Suppl 2):34–39. - PubMed
    1. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9):507–517. doi: 10.1038/nrneurol.2011.121. - DOI - PubMed
    1. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343–1356. doi: 10.1056/NEJMra041347. - DOI - PubMed
    1. Said G. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2006;16(5):293–303. doi: 10.1016/j.nmd.2006.02.008. - DOI - PubMed

Publication types

MeSH terms